Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
150 participants
INTERVENTIONAL
2023-01-01
2023-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Systemic Erythropoietin Injection in Patients Having Optic Atrophy
NCT04680143
Low-dose Atropine for Myopia Control in Children
NCT03865160
Pilocarpine and Brimonidine in Patients With Monofocal Lenses
NCT03825081
Effect of Atropine on Pupil Size and Quality of Vision
NCT06071260
Correction of Anisometropic Amblyopia in Children.
NCT05325021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glaucoma suspect group
Cases diagnosed as glaucoma suspect
Low dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
High dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Post-refractive surgery group
Cases had undergone refractive surgery
Low dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
High dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
High dosage selective alpha-2 receptor agonists topical eyedrop
Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* post-refractive surgery cases.
Exclusion Criteria
* Cases with previous history of any retinal intervention or other drugs that may alter intraocular pressure measurements.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Abdelshafy
Assistant professor of Ophthalmology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed A Abdelshafy, MD
Role: PRINCIPAL_INVESTIGATOR
Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ahmed Abdelshafy
Banhā, QA, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC-2-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.